Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Follow-On Grudge Match: The Round One Scorecard In Waxman vs. Eshoo

Executive Summary

Two versions of biosimilars legislation are now before the House, and the question is how much, if any, compromise will be needed to get a measure approved on that side of Capitol Hill

You may also be interested in...



Follow-On Biologics Legislation Faces Tough Road Ahead; Momentum Stalled

Prospects for enactment of follow-on biologics legislation appear limited in the near term, according to Capitol Hill players in the debate

Follow-On Biologics Legislation Faces Tough Road Ahead; Momentum Stalled

Prospects for enactment of follow-on biologics legislation appear limited in the near term, according to Capitol Hill players in the debate

Follow-On Biologics Bill’s Prospects Are Uncertain, Waxman Staffer Says

Busy House committee schedule and “fractured” Senate will make reaching consensus a challenge, Ann Witt says, but potential inclusion of FOBs into health reform bill is “wildcard.”

Related Content

Topics

UsernamePublicRestriction

Register

ID004339

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel